- Home
- BNZI vs KPRX Comparison
BNZI vs KPRX Comparison
Compare BNZI & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNZI
- KPRX
- Stock Information
- Founded
- BNZI 2016
- KPRX 1998
- Country
- BNZI United States
- KPRX United States
- Employees
- BNZI N/A
- KPRX N/A
- Industry
- BNZI
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- BNZI
- KPRX Health Care
- Exchange
- BNZI Nasdaq
- KPRX Nasdaq
- Market Cap
- BNZI 9.5M
- KPRX 11.0M
- IPO Year
- BNZI N/A
- KPRX N/A
- Fundamental
- Price
- BNZI $1.55
- KPRX $3.31
- Analyst Decision
- BNZI Strong Buy
- KPRX Strong Buy
- Analyst Count
- BNZI 1
- KPRX 1
- Target Price
- BNZI $125.00
- KPRX $10.00
- AVG Volume (30 Days)
- BNZI 1.1M
- KPRX 47.3K
- Earning Date
- BNZI 11-14-2024
- KPRX 11-26-2024
- Dividend Yield
- BNZI N/A
- KPRX N/A
- EPS Growth
- BNZI N/A
- KPRX N/A
- EPS
- BNZI N/A
- KPRX 1.69
- Revenue
- BNZI $4,310,782.00
- KPRX $16,020,000.00
- Revenue This Year
- BNZI $23.28
- KPRX N/A
- Revenue Next Year
- BNZI $66.99
- KPRX N/A
- P/E Ratio
- BNZI N/A
- KPRX $1.96
- Revenue Growth
- BNZI N/A
- KPRX N/A
- 52 Week Low
- BNZI $1.46
- KPRX $3.00
- 52 Week High
- BNZI $828.50
- KPRX $8.98
- Technical
- Relative Strength Index (RSI)
- BNZI 33.35
- KPRX 43.88
- Support Level
- BNZI $1.56
- KPRX $3.20
- Resistance Level
- BNZI $1.82
- KPRX $3.49
- Average True Range (ATR)
- BNZI 0.23
- KPRX 0.19
- MACD
- BNZI 0.02
- KPRX -0.03
- Stochastic Oscillator
- BNZI 8.65
- KPRX 23.44
About BNZI Banzai International Inc.
Banzai International Inc is a marketing technology (MarTech) company that produces data-driven marketing and sales solutions for businesses of all sizes. Its mission is to help its customers accomplish their mission by enabling better marketing, sales and customer engagement outcomes. The company sells its products using a recurring subscription license model typical in SaaS businesses. Pricing tiers for its main product, Demio, are based on the number of host-capable users, desired feature sets, and maximum audience size.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.